Tesamorelin Research Peptide

Tesamorelin is a synthetic research peptide engineered as a stabilized analog of native growth hormone–releasing hormone (GHRH 1–44). Its structure includes a trans-3-hexenoic acid substitution at the second amino acid position, a modification designed to enhance peptide stability in experimental environments. In preclinical and laboratory studies, Tesamorelin interacts with GHRH receptors on pituitary somatotroph cells, initiating intracellular signaling pathways associated with growth hormone synthesis and release. Because of its defined receptor activity and improved structural stability, Tesamorelin is frequently utilized in endocrine and metabolic research exploring GHRH receptor dynamics, peptide pharmacokinetics, and modulation of the somatotropic axis under controlled experimental conditions.

Evidence classification: Tesamorelin has controlled human clinical research using an FDA-approved pharmaceutical formulation for a narrow indication. That evidence does not extend to research-grade material.

Phase 3 randomized, placebo-controlled trials published in 2007 and later examined the pharmaceutical formulation in a specific adult population with HIV-associated abdominal fat accumulation, leading to FDA approval in 2010 for that indication. Subsequent controlled studies examined hepatic fat measurements in related populations.

Tesamorelin binds the GHRH receptor, a class B G-protein-coupled receptor on pituitary somatotrophs. Receptor activation increases cAMP and stimulates synthesis and release of growth hormone. GH in turn stimulates hepatic IGF-1 production, which exerts negative feedback. Because endogenous feedback remains intact, GHRH-receptor agonism is mechanistically distinct from exogenous GH.

Read the full Tesamorelin research overview in the FuelX Research Library.